TrialBlood2012

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

Jorge Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.